Dr. Michel LEVY, CEO of ADDS, will be lecturing on "PATIENTS RECRUITMENT: new approaches to optimize the cost-quality ratio" at the event ‘8ème Réunion Annuelle Laboratoires et CROs, Essais Cliniques 2010’ taking place in Paris on Sept. 29-30, 2010.

About the 8th Annual Meeting of CROs and Pharmaceutical companies, Clinical Trials:
This annual conference is dedicated to regulatory, quality and performance in clinical trials in Europe: new European directives, securing your clinical trials, optimization of the ratio benefit/risk… This meeting will provide up-to-date insights thanks to the participation of the French Health Product Safety Agency (AFSSAPS) and the best experts of French and international pharmaceutical companies and CROs.

About Dr. Michel LEVY:
Doctor in Medicine, Pharmacology, INSEAD. Michel has an experience of more than 25 years in the Pharmaceutical industry where he held leadership positions as European Clinical Research Director for Parke-Davis (Pfizer), Medical Director for Wyeth and Zeneca as well as VP Medical Affairs for Beaufour Ipsen. After taking the management of the European R&D Operations of GENTA Inc., a Californian Biotech company specialized on oligonucleotide antisense technology, Dr. Levy then founded in 1995 Advanced Drug Development Services which has became an European CRO and CSO specialized in clinical trials as well as in safety and risk management services. More